Clinical Trials Directory

Trials / Unknown

UnknownNCT04331951

Sensitivity of Targeted Biopsy Within Sydney Protocol for GIM

Sensitivity of Targeted Biopsy Within Sydney Protocol by Using Narrow Band Imaging for Extensive Gastric Intestinal Metaplasia Diagnosis

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
105 (estimated)
Sponsor
King Chulalongkorn Memorial Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Sensitivity of Targeted Biopsy Within Sydney Protocol by Using Narrow Band Imaging for Extensive Gastric Intestinal Metaplasia Diagnosis Objective: The aim of this study is to evaluate the sensitivity of targeted biopsy within Sydney protocol by using narrow band imaging for Extensive Gastric Intestinal Metaplasia diagnosis Research design: Diagnosis study Sample size: 105 cases Data analysis: The outcomes will be presented using 2 by 2 tables and if the data are normal distribution the categorical data will be analysed using McNemar's test

Detailed description

Background and Rationale: Gastric cancer has been in the top-5 of cancer-related death worldwide. Early detection by screening program in high risk patients is very important. If we can detect pre-malignant lesion eg. gastric intestinal metaplasia, we can provide the appropriate surveillance program to those patients. However, the screening protocol for gastric intestinal metaplasia remained unclear. Recently in July 2019, British Society of Gastroenterology published the guideline on the diagnosis and management of patients at risk of gastric adenocarcinoma. The image-enhanced endoscopy (IEE) is recommended as the best modality for assessing gastric intestinal metaplasia. Additionally, they recommended taking biopsy by using Sydney protocol which means taking biopsy at two areas for antrum, two areas for body and one for incisura although they look normal. We aimed to evaluate the sensitivity of this protocol for extensive gastric intestinal metaplasia (GIM) diagnosis in this study. Methodology: * All patients with history of GIM will be enrolled and undergone standard with white light esophagogastroduodenoscopy (EGD). * Those with suspected lesions of GIM will proceed to narrow band imaging (NBI)-mode endoscopy. * Targeted biopsy will be done at the suspected GIM lesions. Random biopsy will be while will be done if no suspicious GIM lesion seen. Data collection: All data will be processed and recorded by one physician.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTargeted biopsy within Sydney protocolBiopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.

Timeline

Start date
2019-11-01
Primary completion
2021-07-31
Completion
2021-10-31
First posted
2020-04-02
Last updated
2021-04-06

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT04331951. Inclusion in this directory is not an endorsement.